Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial Meeting Abstract
| Authors: | Javle, M.; Borbath, I.; Clarke, S.; Hitre, E.; Louvet, C.; Macarulla, T.; Oh, D.; Spratlin, J.; Valle, J.; Weiss, K.; Berman, C.; Howland, M.; Ye, Y.; Cho, T.; Moran, S.; Abou-Alfa, G. |
| Abstract Title: | Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial |
| Meeting Title: | ESMO 21st World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Jul 3-6 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-07-01 |
| Start Page: | mdz155.224 |
| Language: | English |
| ACCESSION: | WOS:000475860200234 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz155.224 |
| Notes: | Meeting Abstract: P-225 -- Appears on page iv62 of the abstract book -- Source: Wos |
